Phase III trial of the usefulness of new antidepilation conpound, DHL-HisZnNa, against the antineoplastic drug - induced depilation in breast cancer patients - Phase III trial of the usefulness of new antidepilation conpound, DHL-HisZnNa, against the antineoplastic drug - induced depilation in breast cancer patients

开始日期2014-08-04

申办/合作机构-

100 项与 DHL-HisZnNa 相关的临床结果

登录后查看更多信息

100 项与 DHL-HisZnNa 相关的转化医学

登录后查看更多信息

100 项与 DHL-HisZnNa 相关的专利（医药）

登录后查看更多信息

项与 DHL-HisZnNa 相关的文献（医药）

2024-11-12·Proceedings of the National Academy of Sciences

Combatting melioidosis with chemical synthetic lethality

Article

作者: Gallant, Étienne ; Amaya Lopez, Cindy Y. ; Klaus, Jennifer R. ; Zhang, Yifan ; Chandler, Josephine R. ; Davis, Katherine M. ; Seyedsayamdost, Mohammad R. ; McWhorter, Kirklin L. ; Rosen, Paul C. ; Jhunjhunwala, Riddhi

Burkholderia thailandensis has emerged as a nonpathogenic surrogate for Burkholderia pseudomallei , the causative agent of melioidosis, and an important Gram-negative model bacterium for studying the biosynthesis and regulation of secondary metabolism. We recently reported that subinhibitory concentrations of trimethoprim induce vast changes in both the primary and secondary metabolome of B. thailandensis . In the current work, we show that the folate biosynthetic enzyme FolE2 is permissive under standard growth conditions but essential for B. thailandensis in the presence of subinhibitory doses of trimethoprim. Reasoning that FolE2 may serve as an attractive drug target, we screened for and identified ten inhibitors, including dehydrocostus lactone (DHL), parthenolide, and β-lapachone, all of which are innocuous individually but form a chemical-synthetic lethal combination with subinhibitory doses of trimethoprim. We show that DHL is a mechanism-based inhibitor of FolE2 and capture the structure of the covalently inhibited enzyme using X-ray crystallography. In vitro, the combination of subinhibitory trimethoprim and DHL is more potent than Bactrim, the current standard of care against melioidosis. Moreover, unlike Bactrim, this combination does not affect the growth of most commensal and beneficial gut bacteria tested, thereby providing a degree of specificity against B. pseudomallei . Our work provides a path for identifying antimicrobial drug targets and for utilizing binary combinations of molecules that form a toxic cocktail based on metabolic idiosyncrasies of specific pathogens.

2024-10-18·BMJ open

Diabetic health literacy and associated factors among patients with diabetes attending follow-up in public hospitals of Northeastern Ethiopia: a multicentre cross-sectional study.

Article

作者: Demeke, Mekasha Getnet ; Dessie, Yihenew Ayehu ; Goshu, Abel Tibebu ; Worku, Birhan Getye ; Adane, Tigist Demssew ; Nigussie, Elda Mekonnen ; Mengistu, Bethelehem Taye ; Asefa, Eyosiyas Yeshialem

OBJECTIVETo assess the magnitude of diabetic health literacy (DHL) and associated factors among diabetes patients attending follow-up at public hospitals in Northeastern Ethiopia.DESIGNAn institution-based cross-sectional study was conducted from 24 May to 24 June 2022.SETTINGDiabetic clinics of four public hospitals in Northeastern Ethiopia.PARTICIPANTS611 adult diabetes patients who have been undergoing follow-up care for at least 6 months were systematically selected. Patients who were unable to communicate, were critically ill and with gestational diabetes mellitus were excluded from the study.OUTCOMESDHL was assessed using a 15-item tool developed from existing literature.RESULTSOf all the participants, 300 (49.1%) had low, 174 (28.5%) moderate and 137 (22.4%) had high DHL levels. The significant factors impacting DHL included age (<40 years old: AOR=3.48, 95% CI=2.11-5.77; 40-60 years: AOR=2.79, 95% CI=1.75-4.46), low education (AOR=0.29, 95% CI=0.16-0.56 for those who can't read and write; AOR=0.41, 95% CI=0.23-0.74 for those who can read and write; AOR=0.45, 95% CI=0.27-0.76 for primary education), exposure to diabetic education (AOR=1.84, 95% CI=1.31-2.58), having ≥2 information sources (AOR=2.28, 95% CI=1.57-3.32), moderate social support (AOR=1.94, 95% CI=1.32-2.87), strong social support (AOR=2.73, 95% CI=1.75-4.26) and urban residence (AOR=1.65, 95% CI=1.14-2.39).CONCLUSIONThe study showed that less than a quarter of the patients have high DHL, with almost half having low levels of DHL. Tailoring health education programmes to diverse educational levels, incorporating multiple information sources and fostering social support networks could enhance DHL.

2024-08-01·Journal of Chromatography B

Integrated metabolomics and network pharmacology analysis to explore pig bile-processed Rhizoma Coptidis and Fructus Evodiae sauce-processed Rhizoma Coptidis in lipopolysaccharide-induced inflammatory response

Article

作者: Yuan, Zimin ; Gao, Hui ; Wang, Jing ; Yu, Caina ; Wu, Songnan ; Chen, Xuelian

Pig bile- and Fructus Evodiae sauce-processed Rhizoma Coptidis (Danhuanglian, DHL; Yuhuanglian, YHL, respectively) are two types of processed Rhizoma Coptidis (Huanglian, HL) in traditional Chinese medicine (TCM). DHL and YHL are representative of HL generated from the subordinate and counter system processing methods, respectively, both noted for their anti-inflammatory effects. How these processing methods can affect the medicinal efficacy of HL remains a hot topic. Here, we discussed the influence of the two methods on the efficacy of final HL products (i.e., DHL and YHL) by comparing their components and anti-inflammatory mechanisms. Enzyme-linked immunosorbent assay was employed to measure inflammatory factors in RAW264.7 cells induced by lipopolysaccharide, and UPLC-Q-Exactive Orbitrap-MS was utilized to analyze the endogenous differential metabolites of RAW264.7 cells treated with HL, YHL, and DHL, and thus to identify the related metabolic pathways. Finally, using network pharmacology, we constructed a "disease-target-differential metabolites-active ingredients" network map. Compared with the control, all three products, HL, YHL, and DHL, significantly reduced IL-6, TNF-α, and IL-1β levels. 12 differential metabolites related to inflammation were identified and 25 target proteins were overlapping among the three groups. Notably, the anti-inflammatory effects of DHL and YHL were mediated by metabolic pathways such as aminoacyl-tRNA biosynthesis, arginine and proline metabolism, alanine, aspartate and glutamate metabolism, and arginine biosynthesis. Specifically, DHL significantly impacted free fatty acid levels, which was not observed with HL and YHL. On screening, DHL had 9 active ingredients, including three from pig bile, and YHL had 12 active ingredients, with six from the processing excipient Fructus Evodiae. The distinct anti-inflammatory mechanisms and material basis of YHL and DHL were characterized by consistency and distinctiveness. Thus, this study underscores the significant influence of processing methods on the medicinal efficacy of TCMs by revealing their regulatory mechanisms and material bases.

项与 DHL-HisZnNa 相关的新闻（医药）

2023-01-31

·Business Wire

Growth Opportunities in Global Pharmaceutical Logistics 2022: Cold Chain Investments and Hybrid Clinical Trials to Ensure Transformational Growth of Pharmaceutical Logistics - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Growth Opportunities in Global Pharmaceutical Logistics" report has been added to ResearchAndMarkets.com's offering. Medicine production supply chains are currently operating under huge stress due to the war in Ukraine, COVID-19-related disruptions, logistics bottlenecks, and inflation. An energy-related shutdown of production would have a detrimental effect on the supply of critical medicines to patients in the EU and worldwide. The excessive amount of pressure on healthcare supply chains worldwide is driving companies to address vulnerabilities. Pharmaceutical companies will need to rely heavily on an unprecedented level of cooperation from raw material suppliers, government agencies, and contract development and manufacturing organizations. The increasing focus on biologics, adoption of technology, and shift to a patient-centric model are transforming the pharma logistics market; the COVID-19 pandemic has sped up the rate of transformation and acted as a catalyst for the adoption of decentralized trials. This has increased the complexity of coordination of not only clinical trial supply management but also healthcare professionals, and arranging necessary infrastructure for drug storage and infusion. This research analytics on the global pharmaceutical logistics market identifies some of the leading growth opportunity areas in cold chain capabilities for next-generation vaccines and biologics and hybrid trial logistics ensuring patient enrollment and diversity, highlighting the improved last-mile connectivity to propagate the anytime-anywhere care business model. In addition, the market is witnessing the simultaneous adoption of predictive supply chain solutions that optimize pharma operations and improve profitability. Key Topics Covered: 1. Strategic Imperatives Why is it Increasingly Difficult to Grow? The Strategic Imperative 8 The Impact of the Top 3 Strategic Imperatives on the Pharmaceutical Logistics Industry Growth Opportunities Fuel the Growth Pipeline Engine 2. Growth Opportunity Analysis Scope of Analysis Segmentation Market Dynamics Value Chain Analysis Key Competitors Vendor Landscape Growth Drivers for Pharmaceutical Logistics Growth Restraints for Pharmaceutical Logistics Regional Analysis - North America (NA) Regional Analysis - Europe Regional Analysis - United Kingdom (UK) Regional Analysis - Asia-Pacific (APAC) Contract-logistics-provider-related Developments Supply-chain-solution-provider-related Developments CDMO-r CRO-related Developments Pharma LogisticsPrimed for Business Model Disruption 3. Growth Opportunity Universe Growth Opportunity Universe - A Summary Growth Opportunity Universe Summary Growth Opportunity 1: Repurposing Cold Chain Capabilities Global Cold-Chain Products Sales Global Cold-Chain Logistics Spending Global Cold-Chain Logistics Spending Growth Opportunity 2: Hybrid Trial Logistics Case Study - DHL Case Study - Marken (UPS) Growth Opportunity 3: Improved Last-mile Connectivity eCommerce - Disrupting the Traditional Supply Chain Model Case Study - Capsule Growth Opportunity 4: Predictive Supply Chain Case Study - Trek Therapeutics Uses Ambrosus' Blockchain Solution for Quality Control Case Study - Macro-Eyes' ML Solutions Bring Predictability to the Vaccine Supply Chain Companies to Action List of Exhibits Legal Disclaimer A selection of companies mentioned in this report includes Capsule DHL Marken (UPS) For more information about this report visit https://www.researchandmarkets.com/r/24rbgs About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

100 项与 DHL-HisZnNa 相关的药物交易

登录后查看更多信息